HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
trLrTZuRRYEabc2d